Economic Burden of Cardiovascular Diseases in the Russian Federation.
Economic Burden of Cardiovascular Diseases in the Russian Federation.
复制标题
DOI：
10.1016/j.vhri.2013.06.010
复制
发表时间：
2013-09-01
影响因子：
2
通讯作者：
Oganov, Rafael
中科院分区：
文献类型：
--
作者：
Kontsevaya, Anna;Kalinina, Anna;Oganov, Rafael
目的：在俄罗斯联邦，心血管疾病（CVD）是死亡和过早死亡的主要原因，但是，迄今为止，还没有系统的疾病成本的研究，以评估经济的影响CVD.METHODS：CVD的经济负担估计从统计数据的发病率，死亡率和卫生保健资源的使用。卫生保健费用是根据初级、门诊、急诊和住院护理以及药物的支出估计的。非卫生保健费用包括经济损失，由于发病率和过早死亡的工作age.RESULTS：CVD估计花费俄罗斯卢布836.1十亿（24517.8百万）在2006年和1076十亿（24400.4百万）在2009年。心血管疾病的总成本，14.5%，2006年和21.3%，2009年是由于医疗保健，85.5%和78.7%，分别是由于非医疗保健costs.CONCLUSIONS：心血管疾病是一个主要的公共卫生问题。我们首先评估了CVD在俄罗斯的经济负担。我们的研究结果可用于规划预防计划的投资和改善CVD患者护理的措施。今后在联邦、地区和市各级定期监测心血管疾病的经济负担，将有助于评估经济负担的动态，以及在初级和二级预防方面对经济的投资的有效性。由于数据相对不可用，本研究存在重要的局限性，这突出了对更准确的CVD特定信息的需求。
OBJECTIVES: In the Russian Federation, cardiovascular disease (CVD) is the primary cause of death and premature death; however, to date, there have been no systematic cost-of-illness studies to assess the economic impact of CVD.METHODS: The economic burden of CVD was estimated from statistic data on morbidity, mortality, and health care resource use. Health care costs were estimated on the basis of expenditure on primary, outpatient, emergency, and inpatient care, as well as medications. Non-health care costs included economic losses due to morbidity and premature death in the working age.RESULTS: CVD was estimated to cost Russia RUR 836.1 billion (24,517.8 million) in 2006 and RUR 1076 billion (24,400.4 million) in 2009. Of the total costs of CVD, 14.5% in 2006 and 21.3% in 2009 were due to health care, with 85.5% and 78.7%, respectively, due to non-health care costs.CONCLUSIONS: CVD is a leading public health problem. We first assessed the economic burden of CVD in Russia. Our results can be used for planning investments in prevention programs and measures for improving care for patients with CVD. Regular monitoring of the economic burden of CVD in the future at the federal, regional, and municipal levels will allow assessment of the dynamics of economic burden, as well as the effectiveness of investments in the economy in primary and secondary prevention. Because data are relatively unavailable, there are important limitations to this study, which highlight the need for more accurate CVD-specific information.